Scinai Immunotherapeutics Ltd

SCNI

Company Profile

  • Business description

    Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai’s drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

  • Contact

    Hadassah Ein Kerem Campus
    2nd Floor, Jerusalem BioPark
    Jerusalem
    ISR

    T: +972 89302529

    https://www.scinai.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    31

Stocks News & Analysis

stocks

Overpriced ASX listed consumer electronics retailers

Solid balance sheets, lower business risk and strong sales but investors are overly optimistic.
stocks

Nvidia and AMD: Maintain fair value estimate amid reports of Meta’s negotiations to buy Google TPUs

Our update on select stocks from the Semiconductors industry.
stocks

Alphabet: Gemini momentum and possible Meta TPU deal underscore AI capability

We think Alphabet is exceptionally well positioned in everything AI.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,912.002.900.03%
CAC 408,111.0614.630.18%
DAX 4023,797.5371.310.30%
Dow JONES (US)47,427.12314.670.67%
FTSE 1009,688.473.11-0.03%
HKSE25,945.9317.850.07%
NASDAQ23,214.69189.100.82%
Nikkei 22550,167.10608.031.23%
NZX 50 Index13,432.20129.81-0.96%
S&P 5006,812.6146.730.69%
S&P/ASX 2008,617.302.400.03%
SSE Composite Index3,875.2611.080.29%

Market Movers